Compared to Estimates, Humana (HUM) Q2 Earnings: A Look at Key Metrics

Humana (HUM) reported $40.89 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 26.2%. EPS of $7.61 for the same period compares to $6.27 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $40.65 billion, representing a surprise of +0.59%. The company delivered an EPS surprise of +22.35%, with the consensus EPS estimate being $6.22.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Humana performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Benefit ratio - Consolidated: 91.1% versus 91.2% estimated by six analysts on average.
• Medical Membership - Individual Medicare Advantage: 6.45 million versus 6.49 million estimated by five analysts on average.
• Consolidated Operating Cost Ratio: 9.8% versus the five-analyst average estimate of 9.6%.
• Medical Membership - State-based contracts and other: 1.6 million versus the five-analyst average estimate of 1.62 million.
• Revenues- Consolidated- Total services revenue: $1.78 billion versus the six-analyst average estimate of $1.71 billion. The reported number represents a year-over-year change of +27.1%.
• Revenues- Consolidated- Total premiums: $38.83 billion compared to the $38.59 billion average estimate based on six analysts. The reported number represents a change of +26.4% year over year.
• Revenues- Consolidated- Investment income: $253 million versus $235.28 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -7% change.
• CenterWell- Total revenues: $6.79 billion compared to the $6.3 billion average estimate based on six analysts. The reported number represents a change of +22.6% year over year.
• Insurance- Total revenues: $39.14 billion compared to the $38.93 billion average estimate based on six analysts. The reported number represents a change of +25.9% year over year.
• Insurance- Intersegment revenues: $2 million compared to the $1 million average estimate based on five analysts. The reported number represents a change of +100% year over year.
• Insurance- Investment income: $105 million versus the five-analyst average estimate of $118.71 million. The reported number represents a year-over-year change of -38.6%.
• CenterWell- Services revenue- Pharmacy solutions: $382 million compared to the $350.83 million average estimate based on five analysts. The reported number represents a change of +19% year over year.

View all Key Company Metrics for Humana here>>>

Shares of Humana have returned -2.1% over the past month versus the Zacks S&P 500 composite's +1.9% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research